Abstracts
Abstract: Angioplasty (Versus Non-surgical distances did not show a greater improvement m the Management) for Intermittent Claudication angioplasty group. At 2 years of follow-up in one trial F.G.R. Fowkes and I.N. Gillespie the angioplasty group were more likely to have a Date of most recent substantive amendment: patent artery, OR 5.5 (95% CI 1.8, 17.0) but not a 19 February 1998 significantly better walking distance or quality of life.
In the other trial, long-term follow-up at 6 years demonstrated no significant differences in outcome be-
Objectives
tween the angioplasty and control groups.
To determme if angioplasty of arteries in the leg is more effective than non-surgical therapy or no therapy Conclusions in patients with mild to moderate intermittent claudication.
These 
Objectives Data Collection and Analysis
To evaluate the efficacy and safety of fixed-dose subcutaneous low molecular weight heparins compared Data from each trial were obtainedby one reviewer and to adjusted dose intravenous or subcutaneous unincluded the following outcomes: treadmill walking fractionated heparin for the initial treatment of patients distances, ankle brachial pressure mdex, duplex scan-with acute deep venous thrombosis or pulmonary ning results, comphcations of angioplasty and quality embolism. of life.
Search Strategy Main Results
Computerised searches of MEDLINE, EMBASE and Data were obtained from two trials. At 6 months of LILACS, and hand-searching relevant journals for all follow-up, mean ankle brachial pressure radices were publications describing randomised clinical trials of higher in the angioplasty groups than control groups, low molecular weight heparins in the treatment of WMD 0.17 (95% confidence interval (CI) 0.11, 0.24). venous thromboembolism. Additionally, randomised In one trial walking distances were greater in the clinical trials were searched through personal comangioplasty group, but in the other trial in which munication with colleagues and representatives of controls underwent an exercise programme, walkmg pharmaceutical companies.
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Selection Criteria the 2158 patmnts in the low molecular weight heparin group versus 43 (2.0%) of the 2196 patients in the unOnly truly randomlsed clinical trials comparing fixed-fractionated heparin group suffered a major haemdose subcutaneous low molecular weight heparin with orrhage. At the end of follow-up in the low molecular adjusted dose intravenous or subcutaneous un-weight heparin group, 94 (5.2%) of the 1803 patients fractionated heparin in patients with venous throm-had died versus 125 (6.9%) of the 1816 patients m the boembolism were included, unfractionated heparin group. This was also a statistically significant reduction. The analysis of stu&es in patients with proximal deep venous thrombosis (five studies, 1636 patients) showed Data Collection and Analysis a statistically significant reduction in the incidence of recurrent venous thromboembolic events at the end of The search strategy, the inclusion of studies, and the follow-up in favour of low molecular weight heparin evaluation of outcome data on the change in veno-(OR 0.60; 95% CI 0.40-0.89). At the end of follow-up 39 graphic score comparing pre-and post-treatment venograms, the incidence of symptomatic recurrent venous (4.8%) of the 814 patients allocated to low molecular thromboembolism during initial treatment and during weight heparin versus 64 (7.8%) of the 822 patients in the follow-up, the frequency of major haemorrhagic epi-unfractionated heparin group had a recurrent venous sodes during the initial treatment period, and the over-thromboembolic event. In this specific group of patients all mortality at the end of follow-up were performed by the reduction in the frequency of major haemorrhagic two independent reviewers, episodes and in the overall mortality with low moThe main analysis included all trials m patients with lecular weight heparin was also statistically significant.
In patients with pulmonary embolism, however, the venous thromboembohsm. Additional analyses were reduction in recurrent venous thromboembolic events done for specific groups of patients including (i) was relatively small, with a wide 95% confidence inpatients with proximal deep venous thrombosis; (ii) patients with pulmonary embolism; and (iii) patients terval (OR 0.91, 95% CI 0.42-1.97).
The analysis of studies with reported adequate conwith malignant disease, cealment of treatment allocation prior to randomisation (six studies, 3218 patients) demonstrated a statistically non-significant reduction in recurrent venous thromMain Results boembolism during the initial treatment, and a statistically non-significant reduction in overall mortality at Compared to the current standard therapy with un-the end of follow-up in favour of low molecular weight fractionated heparin in patients with venous throm-heparin treatment. boembolism, the therapy with low molecular weight heparm demonstrated a statistically non-significant reduction in recurrent venous thromboembolism of apConclusion proximately 25% during the imtial treatment, at 3 or 6 months' follow-up, or at the end of follow-up. At the The efficacy and safety of low molecular weight heparin end of follow-up 76 (4.2%) of the 1803 patients allocated treatment in patients with deep venous thrombosis to low molecular weight heparin had thrombotic com-and/or pulmonary embollsim was shown to be at least plications versus 101 (5.6%) of the 1816 patients al-as effective as unfractionated heparin treatment. The located to unfractlonated heparin (OR 0 75; 95% outcomes concerning the safety of low molecular confidence interval (CI) 0.55-1.01). Of the patients in-weight heparin, the occurrence of major haemorrhage cluded in this analysis, approximately 25% had pul-during the initial treatment and overall mortality at the monary embolism. A statistically significant difference end of follow-up, demonstrated a statistically slgin venographic outcome was demonstrated m favour nificant reduction in favour of low molecular weight of low molecular weight heparin. A reduction of the heparin. We conclude that low molecular weight hepthrombus size on venogram occurred in 62% of low arin can be safely adopted as the standard therapy in molecular weight heparin treated patients and in 53% patmnts with deep venous thrombosis. Therefore, studof patients treated with unfractionared heparin. The ies comparing the individual low molecular weight observed reduction with low molecular weight heparin heparins with each other in these patients will be jusm the frequency of major haemorrhaglc episodes dur-tlfied. Although the results in patients with pulmonary ing the initial treatment was also statistically sig-embolism are promising, it would be prudent to await nificant. At the end of the mltlal period 23 (1.1%) of further results of new studies.
